Ophthalmic Drugs Market by Disease Type (Allergy, Dry Eye Disorder, Glaucoma, Retinal Disorder), Dispense Type (Over-the-Counter, Prescription) and Forecast 2017-2021

Ophthalmic Drugs Market by Disease Type (Allergy, Dry Eye Disorder, Glaucoma, Retinal Disorder), Dispense Type (Over-the-Counter, Prescription) and Forecast 2017-2021

Many safe and effective OTC ophthalmic drugs or products from artificial tears and ointments to ocular decongestants for mild eye disorders are available for self-treatment. Many common eye (ocular) disorders disappear without treatment or can be managed by self-treating. Some of the prescription medications for eye allergy include eyedrops (decongestant, antihistamine, mast cell stabilizer, corticosteroid, NSAID). allergy shots (immunotherapy), and non-sedating oral antihistamines; while over the counter medication includes artificial tears, decongestant eyedrops, and oral antihistamines. Treatments for dry eye syndrome include artificial tears, gels, or ointments; corticosteroid drops; cyclosporine A drops; and punctal plugs. Supportive therapies to treat underlying causes of dry eye, such as meibomian gland dysfunction, include hot compresses, lid scrubs, and omega-3 supplements. Although there is no cure for glaucoma, IOP-lowering eye drops are the current treatment strategy for most types of the disease. Corticosteroids are currently the only drugs in the United States approved for treating retinal disorders such as non-infectious uveitis, although their long-term use leads to side effects.

The global ophthalmic drugs market segmentation is based on disease type (allergy, dry eye disorder, glaucoma, retinal disorder), and dispense type (over-the-counter, prescription).

The global ophthalmic drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global ophthalmic drugs market research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World. The global ophthalmic drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global ophthalmic drugs market and profiled in this report include Abbott Healthcare, Allergan Plc, Bayer, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer, Inc., Renegeron, Santen Pharmaceuticals Company Ltd., and Valeant Pharmaceuticals, Inc.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Ophthalmic Drugs Market

1. Disease Type
1.1. Allergy
1.2. Dry Eye Disorder
1.3. Glaucoma
1.4. Retinal Disorder

2. Dispense Type
2.1. Over-the-Counter
2.2. Prescription

3. Geography (Region, Country)
3.1. North America (U.S., Canada)
3.2. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.3. Latin America (Brazil, Mexico, Rest of LA)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World (Middle East & Africa)

4. Company Profiles
4.1. Abbott Healthcare
4.2. Allergan Plc
4.3. Bayer
4.4. Johnson & Johnson
4.5. Merck & Co.
4.6. Novartis AG
4.7. Pfizer, Inc.
4.8. Renegeron
4.9. Santen Pharmaceuticals Company Ltd.
4.10. Valeant Pharmaceuticals, Inc.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*

EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish